Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna, +17

Journal of Pharmacology and Experimental Therapeutics

Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis

Judith A. Siuciak, Douglas S. Chapin, John F. Harms, +7

Neuropharmacology

NeuropsychologyPsychiatryPsychotic DisorderPsychotropic MedicationNovel Approach +11

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 <i>H</i> -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).

Patrick R. Verhoest, Douglas S. Chapin, Michael L. Corman, +13

Journal of Medicinal Chemistry

Kinetics of Metastatic Breast Cancer Cell Trafficking in Bone

Pushkar Phadke, Robyn R. Mercer, John F. Harms, +10

Clinical Cancer Research

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models

Vahri Beaumont, Sheng Zhong, Hai Lin, +30

Neuron

Disease ModelsNeurodegenerative DiseasesMolecular NeuroscienceNeurobiology Of DiseaseHuntington ’ +12

Endogenous Osteonectin/SPARC/BM-40 Expression Inhibits MDA-MB-231 Breast Cancer Cell Metastasis

Jennifer E. Koblinski, Benjamin Kaplan-Singer, Sherilyn J. VanOsdol, +9

Cancer Research

A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis

John F. Harms, Danny R. Welch, Rajeev S. Samant, +28

Clinical & Experimental Metastasis

Analysis of mechanisms underlying BRMS1 suppression of metastasis

Rajeev S. Samant, M. Jabed Seraj, Margaret Saunders, +12

Clinical & Experimental Metastasis

Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington’s Disease

Robin J. Kleiman, Lida Kimmel, Susan E. Bove, +8

Journal of Pharmacology and Experimental Therapeutics

Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy

Christine P. Diggle, Stacey J. Sukoff Rizzo, Michael Popiolek, +39

The American Journal of Human Genetics

Biallelic MutationsNeurological DisorderStriatal Pde10aParkinson DiseaseCorticobasal Degeneration +8